International Journal of Copd Dovepress Tiotropium Reduces Risk of Exacerbations Irrespective of Previous Use of Inhaled Anticholinergics in Placebo-controlled Clinical Trials

Background: Data have highlighted the potential bias introduced by withdrawal of inhaled corticosteroids at randomization in chronic obstructive pulmonary disease trials examining inhaled corticosteroids. Analyses were conducted to determine whether this was true of inhaled anticholinergic withdrawal in tiotropium trials. Methods: A pooled analysis of randomized, double-blind, placebo-controlled, parallel-group tiotropium trials of at least six months' duration was performed. Trials had similar inclusion and exclusion criteria. Exacerbation definition was standardized. Patients were divided into two groups, ie, D (anticholinergics discontinued at randomization, previously prescribed) and ND (anticholinergics not discontinued, not previously prescribed). Results: Demographics were balanced between the D (n = 5846) and ND (n = 6317) groups, except for higher cumulative smoking (56 pack-years versus 48 pack-years), lower forced expiratory volume in one second (FEV 1)/forced vital capacity (43% versus 48%), and lower baseline FEV 1 (35.8% predicted versus 42.4% predicted) in the D group. In both groups, tiotropium reduced the risk for an exacerbation (hazard ratio [HR] = 0. Conclusion: Tiotropium reduced exacerbations in patients who did and did not have anticholinergics discontinued upon randomization in clinical trials.

[1]  D. Tashkin,et al.  Rebound hyperresponsiveness to muscarinic stimulation after chronic therapy with an inhaled muscarinic antagonist. , 2015, The American review of respiratory disease.

[2]  J A Anderson,et al.  Methods for therapeutic trials in COPD: lessons from the TORCH trial , 2009, European Respiratory Journal.

[3]  M. Decramer,et al.  A 4-year trial of tiotropium in chronic obstructive pulmonary disease. , 2008, The New England journal of medicine.

[4]  P. Kardos.  Methodological issues in therapeutic trials of COPD , 2008, European Respiratory Journal.

[5]  G. Donaldson,et al.  Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD. , 2008, Revista portuguesa de pneumologia.

[6]  T. Perez,et al.  Effect of tiotropium on health-related quality of life as a primary efficacy endpoint in COPD , 2008, International journal of chronic obstructive pulmonary disease.

[7]  D. Dusser,et al.  The effect of tiotropium on exacerbations and airflow in patients with COPD. , 2006, The European respiratory journal.

[8]  W. MacNee,et al.  Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper , 2004, European Respiratory Journal.

[9]  S. Spencer,et al.  Impact of preventing exacerbations on deterioration of health status in COPD , 2004, European Respiratory Journal.

[10]  P. Calverley,et al.  Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease , 2003, Thorax.

[11]  M. Halpern,et al.  The burden of COPD in the U.S.A.: results from the Confronting COPD survey. , 2003, Respiratory medicine.

[12]  J. van der Palen,et al.  Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. , 2002, American journal of respiratory and critical care medicine.

[13]  T. Seemungal,et al.  Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease , 2002, Thorax.

[14]  R. Zuwallack,et al.  A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease , 2002, European Respiratory Journal.

[15]  C. Sherman,et al.  Effects of withdrawal of inhaled steroids in men with severe irreversible airflow obstruction. , 2001, American journal of respiratory and critical care medicine.

[16]  T. Seemungal,et al.  Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. , 2000, American journal of respiratory and critical care medicine.

[17]  J. Wilson,et al.  Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD. , 1999, Chest.

[18]  S. Yusuf,et al.  Overcoming the limitations of current meta-analysis of randomised controlled trials , 1998, The Lancet.

[19]  L Goldman,et al.  Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments) , 1996, American journal of respiratory and critical care medicine.

[20]  S. Rennard,et al.  Clinical Investigations: COPDExtended Therapy With Ipratropium Is Associated With Improved Lung Function in Patients With COPD: A Retrospective Analysis of Data From Seven Clinical Trials , 1996 .

[21]  P. Jones,et al.  A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. , 1992, The American review of respiratory disease.

[22]  A. Anzueto,et al.  Impact of frequency of COPD exacerbations on pulmonary function, health status and clinical outcomes , 2009 .

[23]  J. Maurer.  Tiotropium in Combination with Placebo, Salmeterol, or Fluticasone-Salmeterol for Treatment of Chronic Obstructive Pulmonary Disease: A Randomized Trial , 2008 .

[24]  F. Maltais,et al.  A randomized controlled trial to assess the efficacy of tiotropium in Canadian patients with chronic obstructive pulmonary disease. , 2007, Canadian respiratory journal.

[25]  J. Maurer.  Prevention of Exacerbations of Chronic Obstructive Pulmonary Disease with Tiotropium, a Once-Daily Inhaled Anticholinergic Bronchodilator: A Randomized Trial , 2007 .

[26]  V. Brusasco,et al.  Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. , 2003, Thorax.